{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T11:26:42Z","timestamp":1777462002883,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003392","name":"Natural Science Foundation of Fujian Province","doi-asserted-by":"publisher","award":["2021J01416"],"award-info":[{"award-number":["2021J01416"]}],"id":[{"id":"10.13039\/501100003392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017686","name":"Fujian Provincial Health Technology Project","doi-asserted-by":"publisher","award":["2022GGA034"],"award-info":[{"award-number":["2022GGA034"]}],"id":[{"id":"10.13039\/501100017686","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejphar.2025.177551","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T23:05:51Z","timestamp":1742943951000},"page":"177551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Drug-associated hyperprolactinemia: A comprehensive disproportionality analysis based on the FAERS database"],"prefix":"10.1016","volume":"996","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1764-2771","authenticated-orcid":false,"given":"Jinhua","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuixian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanxiang","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5629-0348","authenticated-orcid":false,"given":"Jinhua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1622-933X","authenticated-orcid":false,"given":"Huajiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2025.177551_bib1","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3329\/dmcj.v6i2.38219","article-title":"Hyperprolactinemia: a systematic review of diagnosis and management","volume":"6","author":"Akter","year":"2018","journal-title":"Delta Med. Coll. J."},{"key":"10.1016\/j.ejphar.2025.177551_bib2","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1080\/13651501.2018.1425459","article-title":"Prevalence and risk factors of hyperprolactinemia among patients with various psychiatric diagnoses and medications","volume":"22","author":"Alosaimi","year":"2018","journal-title":"Int. J. Psychiatr. Clin. Pract."},{"key":"10.1016\/j.ejphar.2025.177551_bib3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0165-0327(97)00086-4","article-title":"Breast enlargement during chronic antidepressant therapy","volume":"46","author":"Amsterdam","year":"1997","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.ejphar.2025.177551_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/JOE-10-0069","article-title":"New concepts in prolactin biology","volume":"206","author":"Bernichtein","year":"2010","journal-title":"J. Endocrinol."},{"key":"10.1016\/j.ejphar.2025.177551_bib5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.encep.2012.03.002","article-title":"[Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance]","volume":"40","author":"Besnard","year":"2014","journal-title":"Encephale"},{"key":"10.1016\/j.ejphar.2025.177551_bib6","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1592\/phco.29.1.64","article-title":"Antipsychotic-induced hyperprolactinemia","volume":"29","author":"Bostwick","year":"2009","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ejphar.2025.177551_bib7","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1210\/er.2011-1040","article-title":"Molecular mechanisms of prolactin and its receptor","volume":"33","author":"Brooks","year":"2012","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ejphar.2025.177551_bib8","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1177\/0269881107078281","article-title":"Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics","volume":"21","author":"Bushe","year":"2007","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2025.177551_bib9","doi-asserted-by":"crossref","first-page":"506","DOI":"10.3109\/09513590.2015.1017810","article-title":"Hyperprolactinemia: pathophysiology and therapeutic approach","volume":"31","author":"Capozzi","year":"2015","journal-title":"Gynecol. Endocrinol."},{"key":"10.1016\/j.ejphar.2025.177551_bib10","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.psyneuen.2015.04.011","article-title":"Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: a randomized, double-blind, placebo-controlled, dose-response study","volume":"58","author":"Chen","year":"2015","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ejphar.2025.177551_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2023.115300","article-title":"Cardiovascular toxicity induced by SSRIs: analysis of spontaneous reports submitted to FAERS","volume":"326","author":"Chen","year":"2023","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.ejphar.2025.177551_bib12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/0010-7824(91)90115-V","article-title":"Low estrogen oral contraceptives and the hypothalamo-pituitary axis","volume":"44","author":"De Leo","year":"1991","journal-title":"Contraception"},{"key":"10.1016\/j.ejphar.2025.177551_bib13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1080\/01621459.1992.10475190","article-title":"Generalized collinearity diagnostics","volume":"87","author":"Fox","year":"1992","journal-title":"J. Am. Stat. Assoc."},{"key":"10.1016\/j.ejphar.2025.177551_bib14","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s40263-017-0437-9","article-title":"Evaluation of potentially prolactin-related adverse events and sexual maturation in adolescents with schizophrenia treated with paliperidone extended-release (er) for 2 Years: a post hoc analysis of an open-label multicenter study","volume":"31","author":"Gopal","year":"2017","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejphar.2025.177551_bib15","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad","year":"2004","journal-title":"Drugs"},{"key":"10.1016\/j.ejphar.2025.177551_bib16","first-page":"335","article-title":"Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden. Pharmacoepidemiol","volume":"26","author":"Holm","year":"2017","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejphar.2025.177551_bib17","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2265.2010.03814.x","article-title":"Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management","volume":"74","author":"Holt","year":"2011","journal-title":"Clin. Endocrinol."},{"key":"10.1016\/j.ejphar.2025.177551_bib18","first-page":"435","article-title":"Prolactin--not only lactotrophin. A \"new\" view of the \"old\" hormone","volume":"63","author":"Ignacak","year":"2012","journal-title":"J. Physiol. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177551_bib19","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.2174\/1570159X21666221027143920","article-title":"Sex differences in serum prolactin levels in children and adolescents on antipsychotics: a systematic review and meta-analysis","volume":"21","author":"Ilzarbe","year":"2023","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.ejphar.2025.177551_bib20","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3109\/00048674.2011.589044","article-title":"Antipsychotic-induced hyperprolactinaemia","volume":"45","author":"Inder","year":"2011","journal-title":"Aust. N. Z. J. Psychiatr."},{"key":"10.1016\/j.ejphar.2025.177551_bib21","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1124\/jpet.102.035303","article-title":"The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats","volume":"302","author":"Kapur","year":"2002","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejphar.2025.177551_bib22","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1001\/jama.285.16.2114","article-title":"Medication errors and adverse drug events in pediatric inpatients","volume":"285","author":"Kaushal","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.ejphar.2025.177551_bib23","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ejphar.2010.08.026","article-title":"Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats","volume":"647","author":"Kitaichi","year":"2010","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177551_bib24","first-page":"419","article-title":"Hyperprolactinemia after low dose of amisulpride","volume":"25","author":"Kopecek","year":"2004","journal-title":"Neuroendocrinol. Lett."},{"key":"10.1016\/j.ejphar.2025.177551_bib25","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/ijc.35255","article-title":"Cyclin-dependent kinase 4\/6 inhibitors and cardiotoxic events in breast cancer: a pharmacovigilance study based on the FAERS database","volume":"156","author":"Li","year":"2025","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2025.177551_bib26","doi-asserted-by":"crossref","DOI":"10.1111\/jne.12888","article-title":"Metabolic functions of prolactin: physiological and pathological aspects","volume":"32","author":"Lopez-Vicchi","year":"2020","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.ejphar.2025.177551_bib27","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/hup.1116","article-title":"Hyperprolactinemia associated with psychotropics--a review","volume":"25","author":"Madhusoodanan","year":"2010","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2025.177551_bib28","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1046\/j.1365-2125.2003.02007.x","article-title":"Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications","volume":"57","author":"Mangoni","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177551_bib29","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1080\/14712598.2021.1948529","article-title":"The impact of anti-TNF\u03b1 agents on weight-related changes: new insights from a real-world pharmacovigilance study using the FDA adverse event reporting system (FAERS) database","volume":"21","author":"Mazhar","year":"2021","journal-title":"Expet Opin. Biol. Ther."},{"key":"10.1016\/j.ejphar.2025.177551_bib30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2025.177551_bib31","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.pnpbp.2003.09.006","article-title":"Amisulpride: limbic specificity and the mechanism of antipsychotic atypicality","volume":"27","author":"M\u00f6ller","year":"2003","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.177551_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.yfrne.2017.02.003","article-title":"Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics","volume":"45","author":"Montejo","year":"2017","journal-title":"Front. Neuroendocrinol."},{"key":"10.1016\/j.ejphar.2025.177551_bib33","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.4088\/JCP.v65n1108","article-title":"Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment","volume":"65","author":"Montgomery","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.177551_bib34","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/S0895-4356(96)00236-3","article-title":"A simulation study of the number of events per variable in logistic regression analysis","volume":"49","author":"Peduzzi","year":"1996","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.ejphar.2025.177551_bib35","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/BF03262422","article-title":"Paliperidone extended release","volume":"14","author":"Perry","year":"2012","journal-title":"Pediatr. Drugs"},{"key":"10.1016\/j.ejphar.2025.177551_bib36","doi-asserted-by":"crossref","first-page":"S873","DOI":"10.1192\/j.eurpsy.2022.2265","article-title":"Paroxetine-induced galactorrhea","volume":"65","author":"Petrykiv","year":"2022","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.ejphar.2025.177551_bib37","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000054954","article-title":"Effects of sertraline treatment on plasma cortisol, prolactin and thyroid hormones in female depressed patients","volume":"45","author":"Sagud","year":"2002","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.ejphar.2025.177551_bib38","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s40264-013-0061-7","article-title":"Illustration of the weibull shape parameter signal detection tool using electronic healthcare record data","volume":"36","author":"Sauzet","year":"2013","journal-title":"Drug Saf."},{"key":"10.1016\/j.ejphar.2025.177551_bib39","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0306-4530(99)00065-7","article-title":"Effects of subchronic paroxetine administration on night-time endocrinological profiles in healthy male volunteers","volume":"25","author":"Schl\u00f6sser","year":"2000","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.ejphar.2025.177551_bib40","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/schbul\/sbn023","article-title":"Secondary effects of antipsychotics: women at greater risk than men","volume":"35","author":"Seeman","year":"2009","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.ejphar.2025.177551_bib41","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1080\/14740338.2022.2016696","article-title":"A real-world pharmacovigilance study of axitinib: data mining of the public version of FDA adverse event reporting system","volume":"21","author":"Shu","year":"2022","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.ejphar.2025.177551_bib42","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1177\/0269881120903466","article-title":"Sex differences in text-mined possible adverse drug events associated with drugs for psychosis","volume":"34","author":"S\u00f8rup","year":"2020","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2025.177551_bib43","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/00004714-199708000-00009","article-title":"The effect of fluvoxamine on serum prolactin and serum sodium concentrations: relation to platelet 5-HT2A receptor status","volume":"17","author":"Spigset","year":"1997","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.ejphar.2025.177551_bib44","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.874705","article-title":"Risperidone induced hyperprolactinemia: from basic to clinical studies","volume":"13","author":"Stojkovic","year":"2022","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.ejphar.2025.177551_bib45","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S2215-0366(21)00241-8","article-title":"Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland","volume":"8","author":"Taipale","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.ejphar.2025.177551_bib46","first-page":"929","article-title":"Pharmacological causes of hyperprolactinemia","volume":"3","author":"Torre","year":"2007","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.ejphar.2025.177551_bib47","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/0002-9378(91)90645-8","article-title":"A selective serotonin reuptake inhibitor, fluoxetine hydrochloride, modulates the pulsatile release of prolactin in postmenopausal women","volume":"164","author":"Urban","year":"1991","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ejphar.2025.177551_bib48","article-title":"Acute kidney injury associated with remdesivir: a comprehensive pharmacovigilance analysis of COVID-19 reports in FAERS","volume":"13","author":"Wu","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejphar.2025.177551_bib49","article-title":"Efficacy and safety of adjunctive aripiprazole, metformin, and paeoniae-Glycyrrhiza decoction for antipsychotic-induced hyperprolactinemia: a network meta-analysis of randomized controlled trials","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Psychiatr."},{"key":"10.1016\/j.ejphar.2025.177551_bib50","article-title":"Adjunctive aripiprazole treatment for risperidone-induced hyperprolactinemia: an 8-week randomized, open-label, comparative clinical trial","volume":"10","author":"Zhao","year":"2015","journal-title":"PLoS One"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992500305X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992500305X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T13:16:07Z","timestamp":1777382167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429992500305X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":50,"alternative-id":["S001429992500305X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177551","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-associated hyperprolactinemia: A comprehensive disproportionality analysis based on the FAERS database","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177551","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"177551"}}